Exelixis is transforming the challenges of drug development into opportunities to create innovative therapies with significant clinical and commercial potential.

Corporate Profile

Exelixis, Inc., from the Greek word for “evolution,” is a biopharmaceutical company committed to developing and commercializing small molecule therapies with the potential to improve the treatment of cancer.

Over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. The history of our lead compounMore >>

EXEL (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$10.91
Change (%)0.00 (0.00%)
Volume600
Data as of 08/25/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
08/24/16Exelixis Announces Redemption of All Remaining 4.25% Convertible Senior Subordinated Notes Due 2019Printer Friendly Version
08/03/16Exelixis Announces Second Quarter and Year to Date 2016 Financial Results and Provides Corporate UpdatePrinter Friendly Version
07/22/16Ipsen and its Partner Exelixis Receive Positive CHMP Opinion for Cabometyx™ (Cabozantinib) for the Treatment of Advanced RCC in Adults Following Prior VEGF-Targeted Therapy Printer Friendly Version
07/12/16Exelixis to Release Second Quarter 2016 Financial Results on Wednesday, August 3, 2016Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Featured Report
Download Documentation2015 Annual Report (pdf)
Download Documentation2014 Annual Report (pdf)

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.